TABLE 3.
Ongoing metformin based clinical trials evaluating antioxidant metformin properties.
| Title | Number | Dose | Outcome measure | Measure description | Time frame |
|---|---|---|---|---|---|
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS | NCT05653895 | 1000 mg daily | Insulin Resistance | PCOS associated insulin resistance and hyperinsulinemia by HOMA-IR | 6 months |
| Menstural Irregularities | Oligo/Anovulation, Questionnaire based history taking of each participant | ||||
| Anti Mullerian Hormone | Measurement of Anti mullerian hormone by ELISA | ||||
| Dehydroepiandrosterone | Measurement of Dehydroepiandrosterone using ELISA | ||||
| Antioxidant Assays perceived stress response (PSS-14) questionnaire | Measurement of Total AntiOxidant Capacity by FRAP ASSAY | ||||
| Measurement MDA by TBARS | |||||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients | NCT05298670 | 1,000 mg twice daily | Change in IL17 in both arms as measured by ELISA. | Anti-inflammatory marker | After 6 months |
| Percentage of Quality of Life deterioration in both arms measured by MSQOL-54 | Assessment of quality of life for patients, The highest and lowest values refer to the satisfaction degree of patients | ||||
| Change in IL22 in both arms as measured by ELISA. | Anti-inflammatory marker | ||||
| Malondialdehyde in both arms as measured by Colorimetric tests | Antioxidative marker | ||||
| Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome | NCT06045351 | 750 mg once at dinner for 15 days then twice daily | Hyperandrogenism insulin Resistance | hyperandrogenism by Free Androgen Index via Total Testosterone, Steroid Hormone Binding Globulin | 24 weeks |
| oxidative stress | HOMA-IR (serum Insulin, Fasting Blood Glucose) | ||||
| Total Antioxidant Capacity | |||||
| Therapeutic Intervention of Eriomin Associated With Metformin in the Control of Hyperglycemia in Pre-Diabetic Patients (Eriomin + Met) | NCT06005142 | 1000 mg daily | Fasting Glycemia | Dosages of glycemia concentration (mg/dL) before and after intervention with Eriomin/placebo | |
| OGTT Glycemia | Changes in blood glucose 2 h after the OGTT (mg/dL) before and after intervention with Eriomin/placebo | ||||
| HBA1C | Dosages of HBA1C (%) in the blood serum/plasma before and after intervention with Eriomin/placebo | ||||
| Insulin | Dosages of Insulin (µU/mL) in the blood serum/plasma before and after intervention with Eriomin/placebo | ||||
| Blood Lipids profile | |||||
| Antioxidant Capacity | Dosages of cholesterol (mg/dL), HDL-cholesterol (mg/dL) and triglycerides (mg/dL) in the blood serum/plasma before and after intervention with Eriomin/placebo | ||||
| Lipid Peroxidation | Dosages of TEAC (μM) in the blood serum/plasma before and after intervention with Eriomin/placebo | ||||
| Dosages of MDA (mM) the blood serum/plasma before and after intervention with Eriomin/placebo |
ELISA, Enzyme-Linked Immunosorbent Assay; FRAP ASSAY, ferric reducing ability of plasma assay; HBA1C, glycated hemoglobin; HDL, High-Density Lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; IL17, Interleukin 17; IL22, Interleukin MDA, malondialdehyde; mg, milligram; MSQOL-54, Multiple Sclerosis Quality of Life-54; NCT, ClinicalTrials.gov Identifier; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; TEAC, trolox equivalent antioxidant capacity; TBARS, thiobarbituric acid reactive substances.